Compare Orchid Pharma with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs BIOCON - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA BIOCON ORCHID PHARMA/
BIOCON
 
P/E (TTM) x -120.3 31.8 - View Chart
P/BV x 34.5 3.8 909.1% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ORCHID PHARMA   BIOCON
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
BIOCON
Mar-19
ORCHID PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs194707 27.4%   
Low Rs35554 6.3%   
Sales per share (Unadj.) Rs276.591.9 300.8%  
Earnings per share (Unadj.) Rs-79.216.7 -474.0%  
Cash flow per share (Unadj.) Rs-43.524.2 -179.7%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs53.9101.6 53.1%  
Shares outstanding (eoy) m70.45600.00 11.7%   
Bonus / Rights / Conversions ESOP--  
Price / Sales ratio x0.46.9 6.0%   
Avg P/E ratio x-1.437.7 -3.8%  
P/CF ratio (eoy) x-2.626.1 -10.1%  
Price / Book Value ratio x2.16.2 34.2%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m8,067378,330 2.1%   
No. of employees `0002.86.1 45.7%   
Total wages/salary Rs m2,52711,653 21.7%   
Avg. sales/employee Rs Th6,956.18,994.3 77.3%   
Avg. wages/employee Rs Th902.51,900.7 47.5%   
Avg. net profit/employee Rs Th-1,993.01,635.3 -121.9%   
INCOME DATA
Net Sales Rs m19,47755,144 35.3%  
Other income Rs m4071,444 28.2%   
Total revenues Rs m19,88456,588 35.1%   
Gross profit Rs m1,10315,883 6.9%  
Depreciation Rs m2,5194,478 56.3%   
Interest Rs m5,227709 737.2%   
Profit before tax Rs m-6,23612,140 -51.4%   
Minority Interest Rs m209 218.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,123 -5.9%   
Profit after tax Rs m-5,58010,026 -55.7%  
Gross profit margin %5.728.8 19.7%  
Effective tax rate %2.017.5 11.5%   
Net profit margin %-28.718.2 -157.6%  
BALANCE SHEET DATA
Current assets Rs m11,01448,228 22.8%   
Current liabilities Rs m32,06030,376 105.5%   
Net working cap to sales %-108.132.4 -333.8%  
Current ratio x0.31.6 21.6%  
Inventory Days Days9568 138.9%  
Debtors Days Days3486 39.2%  
Net fixed assets Rs m29,44064,130 45.9%   
Share capital Rs m7053,000 23.5%   
"Free" reserves Rs m2,04357,980 3.5%   
Net worth Rs m3,80060,980 6.2%   
Long term debt Rs m9,01815,766 57.2%   
Total assets Rs m46,510121,924 38.1%  
Interest coverage x-0.218.1 -1.1%   
Debt to equity ratio x2.40.3 917.9%  
Sales to assets ratio x0.40.5 92.6%   
Return on assets %-0.88.8 -8.6%  
Return on equity %-146.916.4 -893.2%  
Return on capital %-3.716.8 -22.3%  
Exports to sales %37.928.1 134.7%   
Imports to sales %22.618.9 120.0%   
Exports (fob) Rs m7,37815,506 47.6%   
Imports (cif) Rs m4,40610,399 42.4%   
Fx inflow Rs m7,51315,506 48.5%   
Fx outflow Rs m5,64910,399 54.3%   
Net fx Rs m1,8655,107 36.5%   
CASH FLOW
From Operations Rs m1,68211,546 14.6%  
From Investments Rs m-9,860-7,138 138.1%  
From Financial Activity Rs m6,644-2,417 -274.9%  
Net Cashflow Rs m-1,5352,103 -73.0%  

Share Holding

Indian Promoters % 32.3 40.4 80.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.6 8.4 54.8%  
FIIs % 3.3 10.7 30.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 19.9 277.9%  
Shareholders   84,811 109,995 77.1%  
Pledged promoter(s) holding % 54.9 0.0 137,300.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare ORCHID PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 650 Points, Reclaims 50,000 Mark; Bajaj Finance & IndusInd Bank Top Gainers(09:30 am)

Asian share markets rose in early trade today, shrugging off worries about an increase in regional coronavirus infections and a subdued session on Wall Street.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


May 18, 2021 01:12 PM

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA - SANOFI INDIA COMPARISON

COMPARE ORCHID PHARMA WITH

MARKET STATS